Abstract CN93
Background
Despite the significant survival benefits offered by immune checkpoint inhibitors (ICIs) in advanced non-small cell lung cancer (NSCLC), disease progression is inevitable. A diverse patient-reported QOL scale attempts to predict outcomes for ICI-treated NSCLC patients using machine learning.
Methods
This study analyzed three multicenter trials of atezolizumab (anti-PD-L1) in NSCLC patients with completed baseline EORTC QLQ-C30 V3 and QLQ-LC13 scales. The phase III IMpower150 cohort served as the discovery set, while the phase II BIRCH and phase III OAK cohorts were used for validation. MOVICS was used to compute cluster analysis and cluster predictor indices (CPI). Predictive ability was assessed with time-dependent AUC, validated with external datasets (OAK, BIRCH) using the PAM algorithm.
Results
In the IMpower150 Discovery Set, using ten consensus ensemble clustering algorithms with QOLS data, two subtypes emerged: Cluster 1 (CS1) and Cluster 2 (CS2). CS2 patients had shorter median overall survival (13.14 vs. 21.42 months, hazard ratio [HR] 2.07 [1.64-2.62]; P < 0.0001) and progression-free survival (5.7 vs. 8.3 months, HR 1.70 [1.42-2.04]; P < 0.0001) compared to CS1. Clinical benefit rates for CS2 were 57% compared to 68% for CS1 (P=0.0027). The PAM algorithms were validated with a similar variety of outcomes in external cohorts. CS2 consistently predicted unfavorable OS (OAK, P < 0.0001; BIRCH, P < 0.0001) and PFS (OAK, P = 0.032; BIRCH, P < 0.0001) compared to CS1.
Conclusions
Our study demonstrated the promise of integrative machine learning to effectively analyze QOLS. This approach could be used to predict clinical outcomes in advanced NSCLC patients undergoing atezolizumab immunotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
This research was funded by the National Natural Science Foundation of China, Grant No. 82060475; Chunhui program of the Chinese Ministry of Education, Grant No. HZKY20220231; the Natural Science Foundation of Guizhou Province, Grant No. ZK2022-YB632; Youth Talent Project of Guizhou Provincial Department of Education, Grant No. QJJ2022-224; China Lung Cancer Immunotherapy Research Project, Excellent Young Talent Cultivation Project of Zunyi City, Zunshi Kehe HZ (2023) 142; Future Science and Technology Elite Talent Cultivation Project of Zunyi Medical University, ZYSE-2023-02; Collaborative Innovation Center of Chinese Ministry of Education, Grant No. 2020-39.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
CN105 - Malignant bowel obstruction in advanced cancer: A nurse-led review of symptom management, dietitian involvement and outcomes at two sites of an NHS Hospital Trust
Presenter: Ravindhi Murphy
Session: EONS Poster Display session
Resources:
Abstract
Slides
CN106 - Nurses’ evaluation and education of chemotherapy-induced peripheral neuropathy: A systematic review
Presenter: Cristina Mazzega Fabbro
Session: EONS Poster Display session
Resources:
Abstract
Slides
CN107 - The effect of Orem-based oral self-care protocol on high-dose chemotherapy-related oral mucositis and self-care agency in patients for hematologic malignancies: A randomized controlled study
Presenter: Dilek Eraslan
Session: EONS Poster Display session
Resources:
Abstract
Slides
CN108 - Comparison of symptom distress ranking between oncology nurses and pediatric patients receiving chemotherapy
Presenter: Enes Şimşek
Session: EONS Poster Display session
Resources:
Abstract
Slides